NCT04469907View on ClinicalTrials.gov

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions
Renal Impairment
Interventions
DRUG

AZD9977

Participants will receive a single oral dose of AZD9977 under fasted conditions.

Trial Locations (6)

32216

Research Site, Jacksonville

32720

Research Site, DeLand

32809

Research Site, Orlando

33014

Research Site, Hialeah

45242

Research Site, Blue Ash

91324

Research Site, Northridge

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY